Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Prostate Cell News
Prostate Cell News is an online resource summarizing the latest prostate cell research.
Defining Aging-Associated Factors That Increase Susceptibility to Prostate Cancer
[Endocrine-Related Cancer] The authors take a broad view of both prostate epithelial cell-intrinsic and cell-extrinsic factors that change with age and are likely to contribute to age-related risk of prostate tumorigenesis. For each factor, they discuss the impact of these age-related changes on cancer risk.
Characterization of the Immune Landscape in Healthy Mouse Prostate and during Prostate Cancer Progression
[Oncoimmunology] Using scRNA-sequencing and multiparametric flow-cytometry analysis, researchers comprehensively characterized immune cells in wild-type and PTEN(i)pe−/− mouse prostates, a model that closely recapitulates human prostate cancer.
MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells
[The Prostate] Researchers demonstrated that androgen deprivation therapy (ADT) induces macrophage migration inhibitory factor (MIF) upregulation, which in turn drives prostate cancer cell proliferation via upregulating AMPD2 expression, eventually contributing to the development of resistance to ADT.
FibroGen Initiates Phase II Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
[FibroGen, Inc.] FibroGen, Inc. announced the initiation of the Phase II monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46-expressing cancer lesions in patients with metastatic CRPC.
KBTBD11 Loss Promotes AKT Hyperactivation and Therapeutic Vulnerability in Prostate Cancer
[Oncogene] Scientists demonstrated that KBTBD11 E3 ubiquitin ligase gene is frequently deleted in human prostate cancers and that KBTBD11 loss augments AKT phosphorylation in prostate cancer cells in culture and in patient samples.
Evolving Roles for the Androgen Receptor and Its Protein Interactome in Castration-Resistant Prostate Cancer
[Oncogene] Less traditional transcriptional roles for androgen receptor (AR), such as those impacting non-coding RNAs as well as transcription-independent roles that include AR-dependent splicing programs and translation control have been recognized to contribute to aggressive CRPC features and treatment resistance.
NRG Oncology PREDICT-RT Study Completes Patient Accrual, Tests Individualized Concurrent Therapy and Radiation for High-Risk Prostate Cancer
[NRG Oncology] The NRG Oncology NRG-GU009 study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial’s anticipated accrual completion date.
TRIM24-Mediated K27-Linked Ubiquitination of ULK1 Alleviates Energy Stress-Induced Autophagy and Promote Prostate Cancer Growth in the Context of SPOP Mutation
[Cell Death & Differentiation] Scientists demonstrated that ULK1 expression is positively correlated with both loss-of-function mutations in SPOP and the upregulation of the E3 ubiquitin ligase TRIM24 in human prostate cancer specimens.
Induction of Ferroptosis in Prostate Cancer by CCDC719-13 via TRIM21-Mediated Ubiquitination of SLC7A11
[Cell Death & Differentiation] Scientists revealed that CCDC719-13 expression is markedly reduced in advanced and recurrent prostate cancer, where its low levels serve as an independent predictor of poor prognosis.
A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
[Cancer Research] Investigators developed a peptide-based proteolysis-targeting chimera (PROTAC) drug that specifically targets BRCA2, leading to its degradation in a DDB1-dependent manner.
Disrupting the Interaction between Androgen Receptor and Its Coregulator WDR77 Delays the Growth of Treatment-Resistant Prostate Cancer
[Cell Reports] Researchers demonstrated the therapeutic potential of disrupting interactions between the androgen receptor and its coregulator WDR77. WDR77 stimulates prostate cancer growth, and its overexpression was associated with worse patient survival.
miRNA-Mediated Resistance Mechanisms in Prostate Cancer: Implications for Targeted Therapy and Metastatic Progression
[Medical Oncology] The authors present a novel, mechanism-centered synthesis focused specifically on miRNA-mediated resistance pathways across standard treatment modalities, including androgen deprivation therapy, enzalutamide, docetaxel, and radiotherapy.
Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.
